Boehringer Ingelheim and Gubra send obesity drug candidate to clinical trial

Years of collaboration among Gubra and Boehringer Ingelheim have now entered a new phase after the partnership's first potential drug has entered clinical trials on human subjects.

Photo: Muusfoto / Gubra / PR

The first possible medicament from Danish biotechnology and contract research organization Gubra's partnership with Germany's Boehringer Ingelheim has now entered its first clinical trial phase, the latter informs in a press statement.

Here, the first healthy human subject has received a dose of the drug called GUB002496 in phase I trials, resulting in a milestone payment made to Gubra.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs